Bank of Nova Scotia’s TherapeuticsMD TXMD Stock Holding History

Bank of Nova Scotia’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,000	Closed	-$656K	–	918
2018 Q3	$656K	Buy	+2,000	New	+$613K	﹤0.01%	745

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Bank of Nova Scotia's TXMD Position: Q4 2018 in Review

Bank of Nova Scotia sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 2,000 shares — an estimated $656K sold.

Bank of Nova Scotia first reported a position in TXMD in Q3 2018 and held it in 1 quarter. The position peaked at $656K in Q3 2018. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

Bank of Nova Scotia reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
Bank of Nova Scotia sold 2,000 TherapeuticsMD shares in Q4 2018, an estimated $656K.
Bank of Nova Scotia first reported a position in TherapeuticsMD in Q3 2018 and held it in 1 quarter.
Bank of Nova Scotia's TherapeuticsMD position peaked at $656K in Q3 2018.
140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Bank of Nova Scotia's 13F filing for Q4 2018, filed 11 Feb 2019.